Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 3Completed 3Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1296Carcinoma, Non-Small-Cell Lung 793Neoplasms 787Colorectal Neoplasms 760Stomach Neoplasms 587Carcinoma, Hepatocellular 581Prostatic Neoplasms 514Lung Neoplasms 466Pancreatic Neoplasms 421Rectal Neoplasms 336Recurrence 314Neoplasm Metastasis 308Leukemia, Myeloid, Acute 293Colonic Neoplasms 283Multiple Myeloma 280Lymphoma 276Esophageal Neoplasms 273Uterine Cervical Neoplasms 272Ovarian Neoplasms 263Melanoma 246Head and Neck Neoplasms 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 210Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 187Nasopharyngeal Carcinoma 182Leukemia 173Lymphoma, Non-Hodgkin 171Liver Neoplasms 165Glioblastoma 160Polycystic Ovary Syndrome 157

Interventions

QL1206 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Bone Metastases × Clear all
NCT04550949 2020-09-22

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 3 Unknown
700 enrolled

Bone Metastases

NCT03550508 2018-06-08

JMT103

Shanghai JMT-Bio Inc.

Phase 1 Unknown
36 enrolled

Bone Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡